Announced
Completed
Synopsis
Koch Disruptive Technologies led a $215m Series B round in Immunai, a New York-based biotech company, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.